Jain Umang, Otley Anthony R, Van Limbergen Johan, Stadnyk Andrew W
*Department of Microbiology and Immunology, †Department of Pediatrics, and ‡Department of Community Health and Epidemiology, Dalhousie University, and the IWK Health Centre, Halifax, NS, Canada.
Inflamm Bowel Dis. 2014 Sep;20(9):1628-37. doi: 10.1097/MIB.0000000000000056.
Complement is well appreciated to be a potent innate immune defense against microbes and is important in the housekeeping act of removal of apoptotic and effete cells. It is also understood that hyperactivation of complement, or the lack of regulators, may underlie chronic inflammatory diseases. A pipeline of products to intervene in complement activation, some already in clinical use, is being studied in various chronic inflammatory diseases. To date, the role of complement in inflammatory bowel disease has not received a lot of research interest. Novel genetically modified laboratory animals and experiments using antagonists to complement effector molecules have kindled important research observations implicating the complement system in inflammatory bowel disease pathogenesis. We review the evidence base for the role and potential therapeutic manipulation of the complement cascade in inflammatory bowel disease.
补体作为一种针对微生物的强大天然免疫防御机制已广为人知，并且在清除凋亡细胞和衰老细胞的日常过程中发挥着重要作用。人们也认识到，补体的过度激活或缺乏调节因子可能是慢性炎症性疾病的潜在病因。一系列用于干预补体激活的产品，其中一些已在临床应用，正在各种慢性炎症性疾病中进行研究。迄今为止，补体在炎症性肠病中的作用尚未引起太多研究关注。新型转基因实验动物以及使用补体效应分子拮抗剂进行的实验引发了重要的研究发现，表明补体系统参与炎症性肠病的发病机制。我们综述了补体级联反应在炎症性肠病中的作用及潜在治疗调控的证据基础。
